BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix (BDSX) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has supportive analyst coverage, improving business outlook, and bullish moving averages, but the recent price action is weak with a -10.24% regular-session drop and insider selling is elevated. With no Intellectia buy signals today and mixed near-term trend data, this is better treated as a hold rather than an immediate purchase.
The technical picture is moderately bullish but not ideal for an impatient entry. MACD is positive at 0.622, though the histogram is positively contracting, which suggests momentum is still positive but slowing. RSI_6 at 57.979 is neutral-to-slightly bullish, not overbought. The moving average structure is constructive with SMA_5 > SMA_20 > SMA_200, indicating an uptrend. Key levels show pivot support at 20.332, with resistance at 24.021 and 26.3. However, the stock just had a sharp -10.24% regular-session decline, so short-term weakness is still present. Similar-pattern stats also point to a weak next-day bias (-1.12%) before modest improvement over the next month (3.25%).
["Roth Capital initiated coverage with a Buy rating and $32 target, citing durable top-line growth and market-leading gross margins.", "Canaccord raised its target to $27 from $22 and kept a Buy rating, citing revenue assumptions and operating margin expansion.", "H.C. Wainwright initiated Buy coverage with a $26 target, highlighting operating leverage and a path to sustainable profitability.", "News mentions strong performance from the Nodify CDT lung nodule biomarker test and expectations that Q2 2026 results could support the stock.", "Hedge funds are buying aggressively, with buying up 1991.20% over the last quarter."]
["The stock fell sharply in the regular session by 10.24%, showing immediate selling pressure.", "Insiders are selling, with selling amount up 531.80% over the last month.", "Options data is not showing strong directional conviction, and the available ratios are flat at 0.0.", "The technical momentum is positive but weakening, as the MACD histogram is contracting.", "There is no AI Stock Picker or SwingMax buy signal today."]
No full financial snapshot was available because the provided snapshot returned an error. Still, the latest analyst commentary indicates the business is expected to continue growing revenue and expanding margins, with a path toward adjusted EBITDA breakeven in 2027-2028. The news flow also suggests clinical validation strength for Nodify CDT, which may support commercial momentum. The latest quarter season referenced in the data is Q2 2026, with financial results expected to be a catalyst, but exact quarter numbers were not provided.
Analyst sentiment is clearly positive and has been improving recently. On 2026-06-24 Roth Capital initiated Buy at $32, on 2026-06-18 Canaccord raised its target to $27 from $22 and kept Buy, and on 2026-06-15 H.C. Wainwright initiated Buy at $26. Earlier on 2026-05-05 Canaccord had already raised its target to $22 from $20. The Wall Street pros view is constructive: the bull case centers on durable growth, gross margin strength, operating leverage, and eventual profitability. The main con is that the stock still needs to prove sustained execution and translate optimism into earnings progress.
